ASCO® 2024 Highlights: Presenter Vignette – Daniel Petrylak

Dr. Daniel Petrylak

Daniel Petrylak


Yale School of Medicine

Abstract# 4503, 5011

4503 – Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
5011 – ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.